EPISODE 023
Though initially surprised by Medtronic’s move to buy Covidien, Stacy Enxing Seng says she immediately saw the wisdom of the deal and recognized the opportunity for a fresh start. In an interview, Enxing Seng explains why she left, what she’s been doing, and how her new role at Lightstone Ventures fits her vision for Medtech’s future.
Podcast Guest
Stacy Enxing Seng
Venture Partner & Independent Director
Lightstone Ventures
Stacy currently serves as a Venture Partner with Lightstone Ventures as well as an Independent Director for both public and venture-backed private companies. Prior to Venture/Independent Director work, Stacy spent the last 25 years in medtech, most recently serving as the President of Covidien¹s $1.7B Vascular business. Stacy joined Covidien following its $2.6B acquisition of ev3 Inc., a medtech success that Stacy co-created in 2000 with ev3¹s founding team. Stacy has been involved in the launch of over 20 medtech technologies, more than 10 substantive M&A transactions, and under her operating leadership, a reputation of achieving world class customer and employee engagement.
Stacy currently serves as a non-executive Independent Director for Hill-Rom Holdings, Inc., (NYSE: HRC), Sonova Holding AG (VTX: SOON), and private Spirox, Inc. and Solace Therapeutics. Past Director appointments include FIRE 1 and CVI.
Stacy holds a B.A. Public Policy, Michigan State University and an M.B.A. Harvard University.
Meet Our Host
Geoff Pardo
Geoff has been in medtech for over two decades in both operational and investment roles. He is passionate about the industry potential and sharing stories from the front lines of innovation.